Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
about
The PCSK9 decadePCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabLDL cholesterol, statins and PCSK 9 inhibitorsPCSK9 and triglyceride-rich lipoprotein metabolismNew therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugsHighlights of the year in JACC 2012Residual macrovascular risk in 2013: what have we learned?Profile of evolocumab and its potential in the treatment of hyperlipidemiaProprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesCholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemiaDevelopment of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disordersPCSK9 inhibitors in the prevention of cardiovascular diseaseNew Era of Lipid-Lowering DrugsPCSK9 inhibitors - clinical applicationsPCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the futureLipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptorPCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaSafety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials.Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Claims-based algorithms for identifying Medicare beneficiaries at high estimated risk for coronary heart disease events: a cross-sectional study.Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studiesAlirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc managementA Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic PopulationsA randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects.PCSK9 antibodies for the treatment of hypercholesterolemiaEfficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS SEvolving targets for lipid-modifying therapyDesign and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapyEfficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phaseEfficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trialEfficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
P2860
Q24615397-9368323C-8A59-45F0-8B50-D7B3CC78456AQ26747776-C58C579E-DB5B-4CBB-92DC-63A194B59E59Q26782522-4B51AEB7-6273-4245-BF2B-31BD5D755585Q26796287-925D3B2C-BE60-4F48-BA12-EF743640F4BFQ26863369-618D76B5-8183-4FF3-9D8A-ACA3B2C9C6F2Q26865608-A0971044-AAB1-4DF6-B0AA-ABC73EF71287Q26996039-C4CAD115-C61D-4D34-ABA0-70DE0A715E62Q27004235-00A8A1DB-4B2A-483D-A907-F192C7E83D2EQ27009477-67DEE11E-A605-4AE3-A87D-379353D99EE5Q27013494-AD5F98D8-E76E-401A-A244-FD30F89B06EFQ28070296-FAECD442-4BD3-4919-8190-FD90CFF3EA59Q28071452-390A48F5-7DD9-41C7-BCB2-CB3AE8C6749DQ28072298-E147F57A-86AD-4FC8-8748-9CC94B0E8DF1Q28079757-E10F8F32-39AB-4A5C-A17F-B6A27F3B2804Q28083595-91CFE989-1AD3-443F-86B3-C7B5D24F21E0Q28258969-EA20EE08-8AD3-406E-BCB8-BD9EC12A046DQ28275648-DE67648E-01BC-47CA-931F-4D738CD56DEAQ30833167-65C905AB-5C84-453B-AE5E-0E1C208EF828Q33670893-DD14A455-1E48-4BF2-9FC9-26A05980C61DQ33808620-3929A958-8124-4A7E-B9FF-04DE75123E3AQ33818871-46A7EAE1-C5AB-4E03-AF22-E3C111509B67Q33887783-303D7CF3-03D5-4842-9EB0-5452DBF29246Q33904455-E5AD1B03-0E42-405C-9A7D-0A871579400BQ33914132-65F8D2F7-0168-4483-94E5-72F76ECED487Q34035025-4A706B73-FE43-4AA4-BCC7-046D68BD5638Q34122388-116F5678-19E9-4F9D-8AB4-7711D2BF3FDFQ34238694-5A561924-81AD-41E6-BBB1-0B2A87C4642EQ34430377-9E82E8F8-8775-4417-8ED4-F790781F8447Q34458693-4C9CD251-13DB-4A29-88B0-280CACF56D2EQ34634698-1D761508-A4FE-4EDD-BC96-5EFDAB50260EQ34658086-616ABABF-3CEF-45C4-94AE-C84CB0F74248Q34669942-36D9FF9B-BDF4-4122-88DA-DC14DB9479BFQ34774969-18E027B3-2037-4393-83AB-E2E1669CCC6DQ34805650-A7829341-AAD8-4A99-BB76-D4E751FA43D8Q34880292-4FF35F1A-4FC9-4F46-A962-F9EE71CBEC05Q35141471-A14ACBF5-3573-4D0A-AECE-2E7DABE8EB0DQ35141476-84296867-08E4-4538-A869-6D1AF6AC7B73Q35603530-A431F39A-D3E8-49B1-B997-971CE007448AQ35664577-9361CB1F-A869-4961-A0B0-4B81F1AB5570Q35671077-5B09AA80-8264-4195-AC63-F298B1E6273E
P2860
Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Safety and efficacy of a monoc ...... g stable atorvastatin therapy.
@en
Safety and efficacy of a monoc ...... g stable atorvastatin therapy.
@nl
type
label
Safety and efficacy of a monoc ...... g stable atorvastatin therapy.
@en
Safety and efficacy of a monoc ...... g stable atorvastatin therapy.
@nl
prefLabel
Safety and efficacy of a monoc ...... g stable atorvastatin therapy.
@en
Safety and efficacy of a monoc ...... g stable atorvastatin therapy.
@nl
P2093
P921
P1476
Safety and efficacy of a monoc ...... g stable atorvastatin therapy.
@en
P2093
Anne-Catherine Ferrand
Corinne Hanotin
Dean J Kereiakes
Evan A Stein
James M McKenney
Michael J Koren
P304
P356
10.1016/J.JACC.2012.03.007
P407
P577
2012-03-28T00:00:00Z